Drug Type Small molecule drug |
Synonyms- |
Target |
Mechanism NIS modulators(solute carrier family 5 member 5 modulators), PET imaging(Positron-emission tomography enhancers) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Endometrial Carcinoma | Phase 2 | - | - | |
Multiple Myeloma | Phase 2 | - | - | |
endometrial clear cell carcinoma | Phase 1 | US | 15 Sep 2017 | |
Endometrial Endometrioid Adenocarcinoma | Phase 1 | US | 15 Sep 2017 | |
Endometrial Mixed Carcinoma | Phase 1 | US | 15 Sep 2017 | |
Endometrial Undifferentiated Carcinoma | Phase 1 | US | 15 Sep 2017 | |
Metastatic endometrial cancer | Phase 1 | US | 15 Sep 2017 | |
Relapsed Uterine Corpus Sarcoma | Phase 1 | US | 15 Sep 2017 | |
Uterine Serous Carcinoma | Phase 1 | US | 15 Sep 2017 | |
uterus adenocarcinoma | Phase 1 | US | 15 Sep 2017 |
Phase 1 | Uterine Corpus Cancer | Endometrial Endometrioid Adenocarcinoma | Relapsed Uterine Corpus Sarcoma | endometrial clear cell carcinoma | Endometrial Mixed Carcinoma | Uterine Serous Carcinoma | Metastatic endometrial cancer | Endometrial Undifferentiated Carcinoma | Recurrent Endometrial Cancer | uterus adenocarcinoma | 34 | (Cohort A Dose Level 1) | vfnfrqnxou(unogpxkpzc) = yupxkkjgav jplngdjocc (kcflymgasw, swxeselhlq - mvgdbjygaw) View more | - | 29 Oct 2024 | |
(Cohort A Dose Level 2) | vfnfrqnxou(unogpxkpzc) = ekmusyivta jplngdjocc (kcflymgasw, ftiuogfupu - istwufhuar) View more | ||||||
Phase 1/2 | 8 | (Healthy Volunteers) | lnyjlmgain(wlabfrcnly) = vojarxggjy hfdacyxyaq (optszangba, eyqtqihgsu - xhbizmdgpx) View more | - | 17 May 2019 | ||
(Myeloma Patients) | mijprqobzc(egmhttdgvj) = gygfqkogoq guzedbfhmt (yqipkmpgtm, jlvrtucnej - eiddvyxvtj) View more |